U.S. Liquid Biopsy Market Size, Share, and Growth Forecast, 2026 – 2033

The U.S. liquid biopsy market size is likely to be valued at US$2.1 billion in 2026 and is expected to reach US$5.1 billion by 2033, growing at a CAGR of 13.6% during the forecast period from 2026 to 2033, driven by the rising prevalence of cancer, increasing adoption of non-invasive diagnostic technologies, and the growing focus on precision oncology and personalized treatment strategies. The rising cancer burden in the U.S. and the increasing focus on early detection are accelerating the adoption of advanced diagnostic approaches in clinical practice. In the U.S. alone, more than 2 million new cancer cases are diagnosed each year, underscoring the importance of innovative diagnostic technologies that can support timely clinical decision-making. Globally, WHO projects that the cancer burden will continue to rise significantly, with more than 35 million new cases expected annually by 2050, reflecting increasing population aging, lifestyle risk factors, and improved detection rates. Increasing focus on precision medicine and personalized oncology therapies is driving demand for molecular profiling tools that can guide targeted treatment decisions. Regulatory support and expanding clinical validation studies are strengthening the integration of liquid biopsy tests into routine oncology workflows.